文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

疑似COVID-19住院患者的不尝试心肺复苏(DNACPR)决策:PRIEST观察性队列研究的二次分析

Do not attempt cardiopulmonary resuscitation (DNACPR) decisions in people admitted with suspected COVID-19: Secondary analysis of the PRIEST observational cohort study.
PubMed 文献 · Resuscitation · 2021-05-04
一句话结论疑似COVID-19住院患者中31%在入院当天或之前即记录DNACPR,该组30天死亡率40.7% vs 13.1%,但多数存活至30天且部分接受了器官支持。

本文为PRIEST观察性队列研究的二次分析,纳入13977例疑似COVID-19住院成人,排除1249例DNACPR数据缺失者后分析12748例。早期DNACPR(入院当天或之前)3929/12748(31%),其死亡率40.7% vs 13.1%,任何器官支持使用率11.6% vs 15.7%,但无创通气使用率与晚期/无DNACPR组相近(4.4% vs 3.5%)。多变量分析显示高龄、活动性恶性肿瘤、慢性肺病、体能状态受限及生理指标异常与早期DNACPR记录增加相关,亚裔与早期DNACPR记录减少相关(p=0.001)。作者结论:早期DNACPR决策与已知不良结局预测因素相关,与亚裔呈负相关;多数早期DNACPR患者存活至30天并接受了许多可能挽救生命的干预。

要点

  • 疑似COVID-19住院成人中31%(3929/12748)在入院当天或之前记录DNACPR,该组30天死亡率40.7%,晚期/无DNACPR组13.1%。
  • 早期DNACPR组任何器官支持使用率11.6% vs 晚期/无DNACPR组15.7%,但无创通气使用率相近(4.4% vs 3.5%)。
  • 多变量分析:高龄、活动性恶性肿瘤、慢性肺病、体能状态受限及生理指标异常与早期DNACPR记录增加相关(均p<0.001)。
  • 亚裔与早期DNACPR记录减少相关(p=0.001)。
  • 多数早期DNACPR患者存活至30天,且许多接受了可能挽救生命的干预。

适用人群与场景

  • 疑似COVID-19住院成人,来自PRIEST研究队列;排除DNACPR数据缺失的1249例后分析12748例。

诊断标准与关键阈值

  • 早期DNACPR定义为入院当天或之前记录DNACPR;晚期/无DNACPR定义为无DNACPR或入院当天之后记录。

研究设计与关键结果

  • 研究类型:PRIEST观察性队列研究的二次分析;样本量13977例疑似COVID-19住院成人,排除1249例DNACPR数据缺失后分析12748例。
  • 早期DNACPR组3929/12748(31%),30天死亡率40.7% vs 晚期/无DNACPR组13.1%。
  • 早期DNACPR组任何器官支持使用率11.6% vs 晚期/无DNACPR组15.7%;无创通气使用率4.4% vs 3.5%。
  • 多变量分析:高龄(p<0.001)、活动性恶性肿瘤(p<0.001)、慢性肺病(p<0.001)、体能状态受限(p<0.001)及生理指标异常与早期DNACPR记录增加相关;亚裔与早期DNACPR记录减少相关(p=0.001)。
  • 多数早期DNACPR患者存活至30天,且许多接受了可能挽救生命的干预。

证据类型、等级与局限

  • 证据类型:观察性队列研究的二次分析;注册号ISRCTN28342533。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为早期DNACPR决策与已知不良结局预测因素相关,且与亚裔呈负相关;多数早期DNACPR患者存活至30天并接受了许多可能挽救生命的干预。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

AIMS: We aimed to describe the characteristics and outcomes of adults admitted to hospital with suspected COVID-19 according to their DNACPR decisions, and identify factors associated with DNACPR decisions.

METHODS: We undertook a secondary analysis of 13,977 adults admitted to hospital with suspected COVID-19 and included in the Pandemic Respiratory Infection Emergency System Triage (PRIEST) study. We recorded presenting characteristics and outcomes (death or organ support) up to 30 days. We categorised patients as early DNACPR (before or on the day of admission) or late/no DNACPR (no DNACPR or occurring after the day of admission). We undertook descriptive analysis comparing these groups and multivariable analysis to identify independent predictors of early DNACPR.

RESULTS: We excluded 1249 with missing DNACPR data, and identified 3929/12748 (31%) with an early DNACPR decision. They had higher mortality (40.7% v 13.1%) and lower use of any organ support (11.6% v 15.7%), but received a range of organ support interventions, with some being used at rates comparable to those with late or no DNACPR (e.g. non-invasive ventilation 4.4% v 3.5%). On multivariable analysis, older age (p < 0.001), active malignancy (p < 0.001), chronic lung disease (p < 0.001), limited performance status (p < 0.001), and abnormal physiological variables were associated with increased recording of early DNACPR. Asian ethnicity was associated with reduced recording of early DNACPR (p = 0.001).

CONCLUSIONS: Early DNACPR decisions were associated with recognised predictors of adverse outcome, and were inversely associated with Asian ethnicity. Most people with an early DNACPR decision survived to 30 days and many received potentially life-saving interventions.

REGISTRATION: ISRCTN registry, ISRCTN28342533, http://www.isrctn.com/ISRCTN28342533.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Sutton L, Goodacre S, Thomas B, et al. Do not attempt cardiopulmonary resuscitation (DNACPR) decisions in people admitted with suspected COVID-19: Secondary analysis of the PRIEST observational cohort study. Resuscitation. 2021. PMID: 33961960. doi:10.1016/j.resuscitation.2021.04.028

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。